JPH08501773A - 可溶性補体受容体1の新規なグリコフォーム - Google Patents
可溶性補体受容体1の新規なグリコフォームInfo
- Publication number
- JPH08501773A JPH08501773A JP6505581A JP50558194A JPH08501773A JP H08501773 A JPH08501773 A JP H08501773A JP 6505581 A JP6505581 A JP 6505581A JP 50558194 A JP50558194 A JP 50558194A JP H08501773 A JPH08501773 A JP H08501773A
- Authority
- JP
- Japan
- Prior art keywords
- scr1
- preparation
- tp10hd
- molecule
- glycoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000006834 complement receptors Human genes 0.000 title claims abstract description 35
- 108010047295 complement receptors Proteins 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 claims abstract description 95
- 238000000034 method Methods 0.000 claims abstract description 56
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 27
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 24
- 230000000295 complement effect Effects 0.000 claims abstract description 23
- 229960000103 thrombolytic agent Drugs 0.000 claims abstract description 20
- 239000003527 fibrinolytic agent Substances 0.000 claims abstract description 19
- 230000024203 complement activation Effects 0.000 claims abstract description 14
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 11
- 238000011098 chromatofocusing Methods 0.000 claims abstract description 10
- 206010061218 Inflammation Diseases 0.000 claims abstract description 5
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 150000002482 oligosaccharides Polymers 0.000 claims description 64
- 108090000623 proteins and genes Proteins 0.000 claims description 51
- 235000018102 proteins Nutrition 0.000 claims description 50
- 102000004169 proteins and genes Human genes 0.000 claims description 50
- 239000000463 material Substances 0.000 claims description 36
- 102000003886 Glycoproteins Human genes 0.000 claims description 29
- 108090000288 Glycoproteins Proteins 0.000 claims description 29
- 241000282414 Homo sapiens Species 0.000 claims description 21
- 125000005629 sialic acid group Chemical group 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 10
- 108010058207 Anistreplase Proteins 0.000 claims description 9
- 102000005348 Neuraminidase Human genes 0.000 claims description 9
- 108010006232 Neuraminidase Proteins 0.000 claims description 9
- 108091005804 Peptidases Proteins 0.000 claims description 9
- 239000004365 Protease Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 230000003480 fibrinolytic effect Effects 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229940088598 enzyme Drugs 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 108020004414 DNA Proteins 0.000 claims description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 6
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 6
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 6
- 230000003197 catalytic effect Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 229960005202 streptokinase Drugs 0.000 claims description 6
- 229960005356 urokinase Drugs 0.000 claims description 6
- 101710196208 Fibrinolytic enzyme Proteins 0.000 claims description 5
- 108010023197 Streptokinase Proteins 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 4
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 4
- 229940127126 plasminogen activator Drugs 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 21
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 230000001404 mediated effect Effects 0.000 abstract description 5
- 208000037765 diseases and disorders Diseases 0.000 abstract description 4
- 206010040560 shock Diseases 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 53
- 210000004027 cell Anatomy 0.000 description 32
- 239000000523 sample Substances 0.000 description 32
- 125000002091 cationic group Chemical group 0.000 description 31
- 239000000872 buffer Substances 0.000 description 29
- 239000011780 sodium chloride Substances 0.000 description 27
- 229920001542 oligosaccharide Polymers 0.000 description 25
- 239000003636 conditioned culture medium Substances 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 229920002684 Sepharose Polymers 0.000 description 19
- 238000004128 high performance liquid chromatography Methods 0.000 description 19
- 238000000746 purification Methods 0.000 description 18
- 239000011347 resin Substances 0.000 description 17
- 229920005989 resin Polymers 0.000 description 17
- 238000004587 chromatography analysis Methods 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 206010018910 Haemolysis Diseases 0.000 description 14
- 230000008588 hemolysis Effects 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000001488 sodium phosphate Substances 0.000 description 13
- 229910000162 sodium phosphate Inorganic materials 0.000 description 13
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 230000027455 binding Effects 0.000 description 11
- 102100022133 Complement C3 Human genes 0.000 description 10
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 description 10
- 235000014633 carbohydrates Nutrition 0.000 description 10
- 238000005341 cation exchange Methods 0.000 description 10
- 238000005277 cation exchange chromatography Methods 0.000 description 10
- 239000012510 hollow fiber Substances 0.000 description 10
- 230000010412 perfusion Effects 0.000 description 10
- 150000001720 carbohydrates Chemical class 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 230000005714 functional activity Effects 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 7
- 230000009450 sialylation Effects 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 238000001042 affinity chromatography Methods 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000002523 lectin Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 238000001542 size-exclusion chromatography Methods 0.000 description 6
- -1 sulfoethyl Chemical group 0.000 description 6
- 108090001090 Lectins Proteins 0.000 description 5
- 102000004856 Lectins Human genes 0.000 description 5
- 101100006976 Mus musculus C4b gene Proteins 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 5
- 230000004154 complement system Effects 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 239000012847 fine chemical Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 229930182830 galactose Natural products 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 150000002772 monosaccharides Chemical class 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- 101710186708 Agglutinin Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 4
- 101710146024 Horcolin Proteins 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 101710189395 Lectin Proteins 0.000 description 4
- 101710179758 Mannose-specific lectin Proteins 0.000 description 4
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 4
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000000910 agglutinin Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 3
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000022811 deglycosylation Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001030 gas--liquid chromatography Methods 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 102000046508 human CR1 Human genes 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003345 scintillation counting Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 241000272814 Anser sp. Species 0.000 description 2
- 101100365087 Arabidopsis thaliana SCRA gene Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 2
- 101001011741 Bos taurus Insulin Proteins 0.000 description 2
- 239000012619 Butyl Sepharose® Substances 0.000 description 2
- 240000008853 Datura stramonium Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 108010046016 Peanut Agglutinin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 101150105073 SCR1 gene Proteins 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 101100134054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NTG1 gene Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000002587 anti-hemolytic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 235000008995 european elder Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000026045 iodination Effects 0.000 description 2
- 238000006192 iodination reaction Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 102000014650 luteinizing hormone receptor activity proteins Human genes 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 230000019254 respiratory burst Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 229960001479 tosylchloramide sodium Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WTOIRKBUWMPVHG-VEIQOZLZSA-N (3R,4R,5S,6R)-3-amino-2-hexadecyl-6-(hydroxymethyl)oxane-2,4,5-triol Chemical group CCCCCCCCCCCCCCCCC1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1N WTOIRKBUWMPVHG-VEIQOZLZSA-N 0.000 description 1
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical class C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- OKAHFCCFNVPTED-UHFFFAOYSA-N 3-(2-aminoethyl)-4-methyl-1h-indole-5,6-diol;2-amino-3-methyl-4h-imidazol-5-one;sulfuric acid Chemical compound OS(O)(=O)=O.CN1CC(=O)N=C1N.CC1=C(O)C(O)=CC2=C1C(CCN)=CN2 OKAHFCCFNVPTED-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101100256223 Caenorhabditis elegans cho-1 gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016550 Complement Factor H Human genes 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 102100030886 Complement receptor type 1 Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101710088235 Envelope glycoprotein C homolog Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 241000234283 Galanthus nivalis Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010070476 Haemodialysis complication Diseases 0.000 description 1
- 102400000142 Haptoglobin alpha chain Human genes 0.000 description 1
- 101800000803 Haptoglobin alpha chain Proteins 0.000 description 1
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 1
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 241001521402 Maackia <angiosperm> Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 101100326461 Mus musculus C1ra gene Proteins 0.000 description 1
- 101100326462 Mus musculus C1rb gene Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001524178 Paenarthrobacter ureafaciens Species 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710180012 Protease 7 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000208829 Sambucus Species 0.000 description 1
- 240000006028 Sambucus nigra Species 0.000 description 1
- 235000003142 Sambucus nigra Nutrition 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102000003838 Sialyltransferases Human genes 0.000 description 1
- 108090000141 Sialyltransferases Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000005937 allylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000003171 anti-complementary effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000012511 carbohydrate analysis Methods 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108010033978 factor XIIIb Proteins 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108010042430 galactose receptor Proteins 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 238000006698 hydrazinolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical class OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229930190071 lycoside Natural products 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- QVRVXSZKCXFBTE-UHFFFAOYSA-N n-[4-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)butyl]-2-(2-fluoroethoxy)-5-methylbenzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCCCNC(=O)C1=CC(C)=CC=C1OCCF QVRVXSZKCXFBTE-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 210000000557 podocyte Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 150000007970 thio esters Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 238000005533 tritiation Methods 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.1つまたはそれ以上の複合オリゴ糖構造を含む、精製された可溶性補体受容 体1(sCR1)糖タンパク質分子であって、1つまたはそれ以上の該構造が構 造あたり平均1個またはそれ以上の末端シアル酸残基を含有する、上記の分子。 2.sCR1糖タンパク質分子を含有するsCR1調製物であって、主要なグリ コフォームがクロマトフォーカシングにより測定して5.1より低いかまたはこれ に等しい等電点pIを示し、該分子のpIがノイラミニダーゼ処理後に増加する 、上記の調製物。 3.sCR1分子を含有するsCR1調製物であって、該分子が1つまたはそれ 以上の複合オリゴ糖構造を含み、該オリゴ糖構造の少なくとも約40%がオリゴ糖 構造あたり1個またはそれ以上の末端シアル酸残基を含有する、上記の調製物。 4.前記分子が1つまたはそれ以上の複合オリゴ糖構造を含み、該オリゴ糖構造 の少なくとも約70%がオリゴ糖構造あたり1個またはそれ以上の末端シアル酸残 基を含有する、請求項3に記載の調製物。 5.本質的にsCR1分子からなるsCR1調製物であって、該調製物中のシア ル酸対マンノースのモル比が0.25より大きいかまたはこれに等しい、上記の調製 物。 6.前記糖タンパク質分子の少なくとも40%がクロマトフォーカシングにより測 定して5.1より低いかまたはこれに等しい等電点を示す、請求項2に記載のsC R1調製物。 7.前記糖タンパク質分子の少なくとも75%がクロマトフォーカシ ングにより測定して5.1より低いかまたはこれに等しい等電点を示す、請求項6 に記載のsCR1調製物。 8.脱グリコシル化sCR1の少なくとも25%の機能的補体阻害活性を有する、 請求項1に記載の分子を含有するsCR1調製物。 9.脱グリコシル化sCR1の少なくとも25%の機能的補体阻害活性を有する、 請求項2、3、4または5に記載のsCR1調製物。 10.前記sCR1糖タンパク質のタンパク質バックボーンが、膜貫通領域の最初 のアラニン残基まで(このアラニン残基を含む)のLHR−A、LHR−B、L HR−C、LHR−D、SCR29、およびSCR30領域を含有する、請求項 1に記載の分子。 11.前記sCR1糖タンパク質のタンパク質バックボーンが、膜貫通領域の最初 のアラニン残基まで(このアラニン残基を含む)のLHR−A、LHR−B、L HR−C、LHR−D、SCR29、およびSCR30領域を含有する、請求項 2、3、4または5に記載のsCR1調製物。 12.治療上有効な量の請求項1に記載のsCR1糖タンパク質分子および医薬上 許容される担体または賦形剤を含有する医薬組成物。 13.治療上有効な量の請求項2に記載の調製物および医薬上許容される担体また は賦形剤を含有する医薬組成物。 14.治療上有効な量の請求項3に記載の調製物および医薬上許容される担体また は賦形剤を含有する医薬組成物。 15.治療上有効な量の請求項4に記載の調製物および医薬上許容される担体また は賦形剤を含有する医薬組成物。 16.治療上有効な量の請求項5に記載の調製物および医薬上許容される担体また は賦形剤を含有する医薬組成物。 17.治療上有効な量の血栓溶解剤をさらに含有する、請求項12に記載の医薬組成 物。 18.治療上有効な量の血栓溶解剤をさらに含有する、請求項13に記載の医薬組成 物。 19.治療上有効な量の血栓溶解剤をさらに含有する、請求項14に記載の医薬組成 物。 20.治療上有効な量の血栓溶解剤をさらに含有する、請求項15に記載の医薬組成 物。 21.治療上有効な量の血栓溶解剤をさらに含有する、請求項16に記載の医薬組成 物。 22.前記血栓溶解剤が次の群: (a)プラスミノーゲンアクチベーターまたはその変異型; (b)アニソイル化プラスミノーゲンーストレプトキナーゼーアクチベータ ー複合体; (c) 一本鎖ウロキナーゼ; (d)二本鎖ウロキナーゼ; (e)ストレプトキナーゼ; (f)第1の二本鎖プロテアーゼの1つの鎖を第2の二本鎖プロテアーゼの 1つの鎖に結合させた繊維素溶解活性ハイブリッドタンパク質であって、該第1 または第2のプロテアーゼの少なくとも一方が繊維素溶解活性を示し、それゆえ 、該ハイブリッドタンパク質が繊維素溶解活性に不可欠な触媒部位(除去しうる 遮断基でブロックされていてもよい)を有するもの;および (g)可逆的にブロックされたin vivo繊維素溶解酵素であって、該酵素の 繊維素溶解活性に不可欠な触媒部位が、加水分解の擬一 次速度定数がpH7.4の等張水溶液中37℃で10-6/秒〜10-3/秒の範囲となるよ うな速度で加水分解により除去しうる基でブロックされているもの; から選ばれる、請求項17、18、19、20または21に記載の医薬組成物。 23.患者の炎症または不適当な補体活性化を伴う疾患または障害を治療する医薬 を製造するための請求項1の精製sCR1または請求項2、3、4または5のsC R1調製物の使用。 24.患者の血栓症を治療する医薬を製造するための請求項1の精製sCR1また は請求項2、3、4または5のsCR1調製物の使用。 25.患者の血栓症を治療する医薬を製造するための請求項1の精製sCR1また は請求項2、3、4または5のsCR1調製物および血栓溶解剤の使用であって 、該血栓溶解剤が次の群: (a)プラスミノーゲンアクチベーターまたはその変異型; (b)アニソイル化プラスミノーゲン−ストレプトキナーゼ−アクチベーター 複合体; (c) 一本鎖ウロキナーゼ; (d)二本鎖ウロキナーゼ; (e)ストレプトキナーゼ; (f)第1の二本鎖プロテアーゼの1つの鎖を第2の二本鎖プロテアーゼの1 つの鎖に結合させた繊維素溶解活性ハイブリッドタンパク質であって、該第1ま たは第2のプロテアーゼの少なくとも一方が繊維素溶解活性を示し、それゆえ、 該ハイブリッドタンパク質が繊維素溶解活性に不可欠な触媒部位(除去しうる遮 断基 でブロックされていてもよい)を有するもの;および (g)可逆的にブロックされたin vivo繊維素溶解酵素であって、該酵素の繊 維素溶解活性に不可欠な触媒部位が、加水分解の擬一次速度定数がpH7.4の等 張水溶液中37℃で10-6/秒〜10-3/秒の範囲となるような速度で加水分解により 除去しうる基でブロックされているもの; から選ばれる、上記の使用。 26.患者の成体呼吸窮迫症候群を治療する医薬を製造するための請求項1の精製 sCR1または請求項2、3、4または5のsCR1調製物の使用。 27.患者の移植拒絶反応を治療する医薬を製造するための請求項1の精製sCR 1または請求項2、3、4または5のsCR1調製物の使用。 28.前記移植が異種移植または同種移植である、請求項27に記載の使用。 29.前記患者がヒトである、請求項23に記載の使用。 30.前記患者がヒトである、請求項24に記載の使用。 31.前記患者がヒトである、請求項25に記載の使用。 32.前記患者がヒトである、請求項26に記載の使用。 33.前記患者がヒトである、請求項27に記載の使用。 34.前記患者がヒトである、請求項28に記載の使用。 35.請求項1に記載のsCR1糖タンパク質の調製方法であって、 (a)オリゴ糖鎖をシアリル化する能力がある培養下の噛乳動物宿主細胞にお いて、sCR1のタンパク質バックボーンをコードするDNA分子を、細胞の生 育が栄養素の供給によって制限され ない条件下で発現させ、そして (b)該培養物からsCR1糖タンパク質を単離する、ことからなる方法。 36.(c)段階(b)で得られた物質からシアル酸含有分子を単離することをさ らに含む、請求項35に記載の方法。 37.請求項2、3、4または5に記載のsCR1調製物の調製方法であって、 (a)糖タンパク質のオリゴ糖鎖をシアリル化する能力がある培養下の噛乳動 物宿主細胞において、sCR1糖タンパク質のタンパク質バックボーンをコード するDNA分子を、細胞の生育が栄養素の供給によって制限されない条件下で発 現させ、そして (b)該培養物からsCR1調製物を単離する、ことからなる方法。 38.(c)段階(b)で得られた物質からシアル酸含有分子を単離することをさ らに含む、請求項37に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/927,099 US5456909A (en) | 1992-08-07 | 1992-08-07 | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
US927,099 | 1992-08-07 | ||
PCT/US1993/007406 WO1994003603A1 (en) | 1992-08-07 | 1993-08-06 | Novel glycoforms of soluble complement receptor 1 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08501773A true JPH08501773A (ja) | 1996-02-27 |
JP3662250B2 JP3662250B2 (ja) | 2005-06-22 |
Family
ID=25454172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50558194A Expired - Lifetime JP3662250B2 (ja) | 1992-08-07 | 1993-08-06 | 可溶性補体受容体1の新規なグリコフォーム |
Country Status (15)
Country | Link |
---|---|
US (3) | US5456909A (ja) |
EP (1) | EP0656061B1 (ja) |
JP (1) | JP3662250B2 (ja) |
CN (1) | CN1089951A (ja) |
AT (1) | ATE253591T1 (ja) |
CA (1) | CA2141842C (ja) |
DE (1) | DE69333287T2 (ja) |
DK (1) | DK0656061T3 (ja) |
ES (1) | ES2210241T3 (ja) |
IL (1) | IL106558A (ja) |
MX (1) | MX9304800A (ja) |
PT (1) | PT656061E (ja) |
TW (1) | TW386878B (ja) |
WO (1) | WO1994003603A1 (ja) |
ZA (1) | ZA935728B (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005308697A (ja) * | 2004-04-26 | 2005-11-04 | Mitsubishi Chemicals Corp | 糖鎖分離方法、検体分析方法、液体クロマトグラフィー装置、並びに糖鎖分析方法及び糖鎖分析装置 |
JP2007537299A (ja) * | 2004-05-14 | 2007-12-20 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 補体活性を阻害することによる同種移植片の生存の延長 |
JP2013538232A (ja) * | 2010-09-15 | 2013-10-10 | セルデックス セラピューティクス インコーポレイテッド | 可溶性補体受容体I型(sCR1)を用いる慢性腎症の処置 |
JP2021004261A (ja) * | 2009-06-26 | 2021-01-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395888B1 (en) * | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
US5456909A (en) * | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
PT730608E (pt) * | 1993-05-17 | 2002-09-30 | Avant Immunotherapeutics Inc | Composicoes compreendendo hidratos de carbono e proeinas relacionadas pelo complemento e metodos para produzir e utilizar as referidas composicoes |
JP3971797B2 (ja) * | 1994-09-23 | 2007-09-05 | アレクション・ファーマシューティカルズ・インク | 炎症性関節疾患の治療方法 |
GB9614871D0 (en) | 1996-07-15 | 1996-09-04 | Smithkline Beecham Plc | Compounds |
US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
EP3056516A1 (en) * | 1998-02-20 | 2016-08-17 | Genentech, Inc. | Inhibitors of complement activation |
US6956107B2 (en) * | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
SE0004808D0 (sv) * | 2000-12-20 | 2000-12-20 | Apbiotech Ab | Method for the purification of an enzyme |
CA2459040A1 (en) * | 2001-09-14 | 2003-03-27 | Mimeon, Inc. | Methods of making glycolmolecules with enhanced activities and uses thereof |
US20040214228A9 (en) * | 2001-09-14 | 2004-10-28 | Ganesh Venkataraman | Methods of evaluating glycomolecules for enhanced activities |
AU2004232858B2 (en) | 2003-04-23 | 2009-07-09 | Mannkind Corporation | Hydraulically actuated pump for long duration medicament administration |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
WO2006014425A1 (en) | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Methods and devices for delivering glp-1 and uses thereof |
US20070004625A1 (en) * | 2005-06-30 | 2007-01-04 | Li Liang-Man | Use of complement inhibitory proteins to treat spinal cord injury |
EP1738763A1 (en) | 2005-06-30 | 2007-01-03 | AVANT Immunotherapeutics, Inc. | Use of complement inhibitory proteins to treat spinal cord injury |
GB0518443D0 (en) * | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
CN101355956A (zh) * | 2005-11-04 | 2009-01-28 | 健泰科生物技术公司 | 利用补体途径抑制剂治疗眼部疾病 |
NZ597215A (en) * | 2005-12-20 | 2012-11-30 | Bristol Myers Squibb Co | Compositions and methods for producing a composition |
AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
RU2445975C2 (ru) * | 2006-03-02 | 2012-03-27 | Алексион Фармасьютикалз, Инк. | Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента |
MX2008011323A (es) | 2006-03-08 | 2008-11-18 | Archemix Corp | Aptameros que se unen al complemento y agentes anti-c5 utiles en el tratamiento de trastornos oculares. |
JP2009530299A (ja) | 2006-03-15 | 2009-08-27 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
CA2646324C (en) | 2006-03-30 | 2016-06-07 | Valeritas, Llc | Multi-cartridge fluid delivery device |
WO2008030505A2 (en) * | 2006-09-05 | 2008-03-13 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
WO2008048675A2 (en) * | 2006-10-20 | 2008-04-24 | Celldex Therapeutics, Inc. | Treatment for age-related macular degeneration and other diseases of the eye |
LT2907827T (lt) | 2006-11-02 | 2018-12-10 | Genentech, Inc. | Humanizuoti anti-d-faktoriaus antikūnai ir jų panaudojimai |
CN107090017A (zh) | 2007-07-09 | 2017-08-25 | 健泰科生物技术公司 | 在多肽的重组生产期间防止二硫键还原 |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
MX2012011648A (es) | 2010-04-07 | 2012-11-29 | Momenta Pharmaceuticals Inc | Glicanos de alta manosa. |
EP2632476B1 (en) | 2010-10-27 | 2017-06-14 | Celldex Therapeutics, Inc. | Method of improving transplant function using soluble complement receptor type i (scr1) |
WO2012125553A2 (en) | 2011-03-12 | 2012-09-20 | Momenta Pharmaceuticals, Inc. | N-acetylhexosamine-containing n-glycans in glycoprotein products |
WO2013013193A1 (en) * | 2011-07-20 | 2013-01-24 | Zepteon, Incorporated | Polypeptide separation methods |
US9695244B2 (en) | 2012-06-01 | 2017-07-04 | Momenta Pharmaceuticals, Inc. | Methods related to denosumab |
EP2855533A4 (en) | 2013-03-15 | 2015-11-25 | Momenta Pharmaceuticals Inc | METHODS RELATING TO CTLA4-FC FUSION PROTEINS |
ES2708759T3 (es) | 2013-05-13 | 2019-04-11 | Momenta Pharmaceuticals Inc | Procedimientos para el tratamiento de la neurodegeneración |
CN107318267B (zh) | 2013-08-12 | 2021-08-17 | 豪夫迈·罗氏有限公司 | 用于治疗补体相关的病症的组合物和方法 |
EP3058084A4 (en) | 2013-10-16 | 2017-07-05 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
EA201692109A1 (ru) | 2014-05-01 | 2017-03-31 | Дженентек, Инк. | Варианты антител к фактору d и их применение |
US10654932B2 (en) | 2015-10-30 | 2020-05-19 | Genentech, Inc. | Anti-factor D antibody variant conjugates and uses thereof |
EP3368074A2 (en) | 2015-10-30 | 2018-09-05 | Hoffmann-La Roche AG | Anti-factor d antibodies and conjugates |
HUE067014T2 (hu) * | 2018-05-16 | 2024-09-28 | Csl Ltd | Szolúbilis 1-es típusú komplementreceptor variánsai és alkalmazásuk |
EP3581203A1 (en) * | 2018-06-11 | 2019-12-18 | Laboratoire Français du Fractionnement et des Biotechnologies | Antibodies with increased activity in the digestive tract |
WO2023240322A1 (en) * | 2022-06-17 | 2023-12-21 | CSL Innovation Pty Ltd | Purification of soluble complement receptor and variants thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5212071A (en) * | 1988-04-01 | 1993-05-18 | The Johns Hopkins University | Nucleic acids encoding a human C3b/C4b receptor (CR1) |
US5079353A (en) * | 1987-12-02 | 1992-01-07 | Chembiomed, Ltd. | Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation |
US5256642A (en) * | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
IL89790A (en) * | 1988-04-01 | 2002-05-23 | Johns Hopking University | Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification |
JPH06503344A (ja) * | 1990-12-06 | 1994-04-14 | ティーセル サイエンシズ,インコーポレーテッド | 可溶性の補体受容体と、補体を抑制しかつ/または免疫活性を抑制する化合物との相乗組成物 |
US5456909A (en) * | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
-
1992
- 1992-08-07 US US08/927,099 patent/US5456909A/en not_active Expired - Lifetime
-
1993
- 1993-08-02 IL IL10655893A patent/IL106558A/en not_active IP Right Cessation
- 1993-08-06 DK DK93918681T patent/DK0656061T3/da active
- 1993-08-06 MX MX9304800A patent/MX9304800A/es unknown
- 1993-08-06 AT AT93918681T patent/ATE253591T1/de not_active IP Right Cessation
- 1993-08-06 WO PCT/US1993/007406 patent/WO1994003603A1/en active IP Right Grant
- 1993-08-06 EP EP93918681A patent/EP0656061B1/en not_active Expired - Lifetime
- 1993-08-06 JP JP50558194A patent/JP3662250B2/ja not_active Expired - Lifetime
- 1993-08-06 ES ES93918681T patent/ES2210241T3/es not_active Expired - Lifetime
- 1993-08-06 ZA ZA935728A patent/ZA935728B/xx unknown
- 1993-08-06 PT PT93918681T patent/PT656061E/pt unknown
- 1993-08-06 CA CA002141842A patent/CA2141842C/en not_active Expired - Lifetime
- 1993-08-06 DE DE69333287T patent/DE69333287T2/de not_active Expired - Lifetime
- 1993-08-07 CN CN93117624A patent/CN1089951A/zh active Pending
-
1994
- 1994-01-21 TW TW082108937A patent/TW386878B/zh not_active IP Right Cessation
-
1995
- 1995-06-06 US US08/470,867 patent/US5858969A/en not_active Expired - Lifetime
-
1998
- 1998-11-05 US US09/186,827 patent/US6057131A/en not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005308697A (ja) * | 2004-04-26 | 2005-11-04 | Mitsubishi Chemicals Corp | 糖鎖分離方法、検体分析方法、液体クロマトグラフィー装置、並びに糖鎖分析方法及び糖鎖分析装置 |
JP2007537299A (ja) * | 2004-05-14 | 2007-12-20 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 補体活性を阻害することによる同種移植片の生存の延長 |
JP2013032391A (ja) * | 2004-05-14 | 2013-02-14 | Alexion Pharmaceuticals Inc | 補体活性を阻害することによる同種移植片の生存の延長 |
JP2021004261A (ja) * | 2009-06-26 | 2021-01-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
JP2013538232A (ja) * | 2010-09-15 | 2013-10-10 | セルデックス セラピューティクス インコーポレイテッド | 可溶性補体受容体I型(sCR1)を用いる慢性腎症の処置 |
Also Published As
Publication number | Publication date |
---|---|
EP0656061A1 (en) | 1995-06-07 |
DE69333287D1 (de) | 2003-12-11 |
ES2210241T3 (es) | 2004-07-01 |
AU4804193A (en) | 1994-03-03 |
ZA935728B (en) | 1994-03-03 |
DE69333287T2 (de) | 2004-09-23 |
IL106558A (en) | 1998-10-30 |
CA2141842C (en) | 2008-07-29 |
MX9304800A (es) | 1994-05-31 |
CN1089951A (zh) | 1994-07-27 |
WO1994003603A1 (en) | 1994-02-17 |
JP3662250B2 (ja) | 2005-06-22 |
TW386878B (en) | 2000-04-11 |
ATE253591T1 (de) | 2003-11-15 |
EP0656061B1 (en) | 2003-11-05 |
IL106558A0 (en) | 1993-12-08 |
US5858969A (en) | 1999-01-12 |
CA2141842A1 (en) | 1994-02-17 |
US6057131A (en) | 2000-05-02 |
US5456909A (en) | 1995-10-10 |
DK0656061T3 (da) | 2004-03-15 |
PT656061E (pt) | 2004-03-31 |
AU670453B2 (en) | 1996-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08501773A (ja) | 可溶性補体受容体1の新規なグリコフォーム | |
EP0362531B1 (en) | A human rhinovirus receptor protein that inhibits virus infectivity | |
JP2879079B2 (ja) | 成長ホルモンレセプター | |
JPH05504053A (ja) | ヒトC3b/C4bレセプター(CR1) | |
JPH04501502A (ja) | ヒトC3b/C4bレセプター (CR1) | |
CZ305602B6 (cs) | Polypeptidická proteáza štěpící von Willebrandův faktor (vWF), nukleová kyselina kódující tento polypeptid a použití tohoto polypeptidu | |
JP2005170954A (ja) | 新規p−セレクチンリガンド蛋白 | |
JPH05501398A (ja) | 組換え産生したヒト細胞膜補助因子タンパク(mcp) | |
JPH0284192A (ja) | 哺乳動物の14―β―ga1レクチン類 | |
US5336667A (en) | Method for inhibiting the ahesion of platelet with alboaggregins: platelet agonists which bind to platelet membrane glycoprotein IB | |
AU650066B2 (en) | Cell growth inhibitors | |
IE83449B1 (en) | Cell growth inhibitors | |
JPH08509720A (ja) | 白血球接着阻害 | |
Hatton et al. | Catabolism of plasminogen glycoforms I and II in rabbits: relationship to plasminogen synthesis by the rabbit liver in vitro | |
AU670453C (en) | Novel glycoforms of soluble complement receptor 1 | |
Lindqvist et al. | Isolation of plaice (Pleuronectes platessa) α1-microglobulin: conservation of structure and chromophore | |
AU2019366008B2 (en) | Drug for treating and/or improving septicemia associated with coagulation abnormality | |
CN103370340A (zh) | 包含dhFas-1结构域和MMP底物的融合肽及其在预防和治疗类风湿性关节炎中的应用 | |
EP1094077A1 (en) | Novel sugar chain-bonded thrombomodulin-like peptide | |
PT91500A (pt) | Processo para a preparacao de antigenio de nefrite clonado | |
AU2002303496A2 (en) | Methods of using a hyaluronan receptor | |
KAWASHIMA et al. | Monoclonal antibodies against human platelet membrane glycoprotein IIIa and collagen-induced platelet activation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040120 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040330 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040519 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040601 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050208 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050308 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050323 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090401 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100401 Year of fee payment: 5 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100401 Year of fee payment: 5 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110401 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120401 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120401 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130401 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140401 Year of fee payment: 9 |
|
EXPY | Cancellation because of completion of term |